AB-CHMINACA is a potent, indazole-based
AB-Chminaca Spray synthetic cannabinoid that acts as a powerful agonist of the body’s cannabinoid receptors. It is often encountered in illicit “Spice”-type herbal blends where the liquid form of the substance has been unevenly sprayed over the plant material, which leads to highly variable and unpredictable effects in users.
Key Facts
Potency: AB-CHMINACA is significantly more potent than the THC found in natural cannabis, with some studies in mice suggesting it is 11 to 58 times stronger. Its high efficacy at the CB1 receptor contributes to its intense effects.
Legal Status: In the United States, AB-CHMINACA is classified as a Schedule I controlled substance, meaning it has no currently accepted medical use and a high potential for abuse.
Use and Form: It was originally developed by Pfizer in 2009 as a potential medicinal drug but was later abandoned due to harmful effects and emerged on the illicit drug market as a substance of abuse around 2013. It is primarily found as a powder or a liquid solution used to create "herbal incense" products for smoking or vaping.
Detection: Standard THC drug tests cannot detect synthetic cannabinoids like AB-CHMINACA due to their different chemical structure. Detection requires specific and sensitive chromatographic techniques such as GC/MS or LC/MS. Health Risks and Side Effects AB-Chminaca Spray
AB-CHMINACA use is associated with a range of severe adverse effects and has been linked to numerous hospitalizations and deaths. Symptoms can vary widely due to inconsistent dosing in street products.
Observed adverse effects include:
Neurological/Psychiatric: Agitation, confusion, lethargy, slurred speech, lack of coordination, convulsions, seizures, and acute psychosis.
Physical: Gastrointestinal distress (nausea/vomiting), cardiorespiratory issues, acute kidney injury, and liver damage.
Chronic Effects: Even at low doses, chronic administration has been shown to cause significant histotoxic effects on the liver and kidneys in animal studies, which may not present with obvious clinical symptoms until advanced stages. The lack of consistent manufacturing and the presence of other toxic contaminants (such as the rat poison brodifacoum in some cases) further amplify the health dangers.
About this series
EMCDDA Risk Assessments are publications
examining the health and social risks of
individual new psychoactive substances.
The Risk Assessment Report consists of an
analysis of the scientific and law enforcement
information available on the new psychoactive
substance under scrutiny and the implications
of placing it under control. It is the outcome of
a meeting convened under the auspices of the
EMCDDA Scientific Committee.
This process is part of a three-step procedure
involving information exchange/early warning,
risk assessment and decision-making in the
framework of Council Decision 2005/387/JHA.